摘要
携带乙肝病毒的非肝脏移植患者其潜在的乙肝病毒再激活风险已经受到多个肾移植中心、骨髓移植中心、健康生殖中心等的广泛重视,我院发生1例肾移植患者携带乙肝病毒,移植后服用肾上腺皮质激素、免疫抑制剂治疗后出现体内病毒大量复制,及时选用恩替卡韦抗病毒治疗,患者原发耐药,给治疗造成一定困惑。经DNA序列检测及时调整用药,治疗获得成功。结合文献和共识,提高非肝脏移植前患者筛查,预防病毒激活。为移植中心和肝病科医生提供一定的参考。
Reactivation risks of hepatitis B virus(HBV) of non liver transplant patients with HBV has been paid extensive attention by multiple renal transplantation centers, bone marrow transplantation centers and healthy reproductive centers. One case renal transplantation patient with HBV in our hospital had massive virus replication in vivo after treatment of adrenocortical hormone and immunodepressants after transplantation, which was treated with entecavir antivirus in time. Primary drug resistance of patient brought some certain perplexity for treatment. Treatment was successful based on DNA sequence test and timely medication adjustment. Combined with literature and consensus, the article discusses screening improvement of non liver transplant patients to prevent viral activation, and provide some certain reference for transplant center and hepatology doctors.
作者
张巍
黄政宇
张景昆
ZHANG Wei;HUANG Zheng-yu;ZHANG Jing-kun(Department of Infection,Pingquan City Hospital,Chengde,Hebei,06750)
出处
《智慧健康》
2018年第21期29-30,共2页
Smart Healthcare
基金
中西医结治疗顽固性腹水
编号:201021098
关键词
肾移植
携带乙肝病毒
原发耐药
Renal transplantation
Carrying hepatitis B virus
Primary drug resistance